Kalaris Therapeutics (KLRS) Proxy Filing summary

Executive summary

• Annual meeting scheduled for August 12, 2025, to be held exclusively online for shareholders of record as of June 25, 2025.

• Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report on Form 10-K, are available online, with paper or email copies available upon request by August 1, 2025.

Voting matters and shareholder proposals

• Shareholders will vote on the election of two Class II directors for three-year terms expiring at the 2028 annual meeting.

• Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, is on the agenda.

• Other business may be transacted as appropriate at the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends voting FOR each director nominee and FOR the auditor ratification proposal.

• Director nominees are Srinivas Akkaraju, M.D., Ph.D., and Andrew Oxtoby.